4-(1-methyl-1-phenylethyl)imidazole | 851539-72-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-methyl-1-phenylethyl)imidazole
• 英文别名: 4(5)-α, α-dimethylbenzylimidazole；4-(1-Methyl-1-phenylethyl) imidazole；5-(2-phenylpropan-2-yl)-1H-imidazole
• CAS: 851539-72-5
• 化学式: C₁₂H₁₄N₂
• 分子量: 186.257
• InChiKey: DSQKYRIBXMYARN-UHFFFAOYSA-N

物化性质

• 沸点：
  357.1±11.0 °C(Predicted)
• 密度：
  1.068±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-iodo-1-phenethylimidazole-2-carbaldehyde 、 4-benzyl-1-phenethylimidazole 、 4-(1-methyl-1-phenylethyl)imidazole 生成 2-(1-methyl-1-phenylethyl)-4-(1-methylpiperidin-4-yloxy)-9,10-dihydro-4H-3,10a-diazabenzo[f]azulene
  参考文献：
  名称：

  6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands

  摘要：

  本专利申请涉及H4受体的新配体，它们的制备过程以及它们的治疗用途。

  公开号：

  US09255101B2
• 作为产物：
  描述：

  2-甲基-2-苯基丙腈 、 (三甲基硅基)甲基化异腈 生成 4-(1-methyl-1-phenylethyl)imidazole
  参考文献：
  名称：

  Process for the synthesis of imidazoles

  摘要：

  本发明提供了一种通过将氰基化合物与硅烷基异氰化合物反应制备咪唑的方法。这些咪唑是有用的药理活性化合物和/或用于制备药理活性化合物的中间体。

  公开号：

  US20050101785A1

文献信息

• Methods for treating CNS disorders with 4-imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197622A1

  公开（公告）日：2007-08-23

  The present invention relates to methods for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, Ar, R 1 , R 1′ , R 2 , and n are as defined in the specification and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神疾病，如精神分裂症、神经疾病，如帕金森病、神经退行性疾病，如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收的障碍、体温稳态的障碍和功能障碍、睡眠和昼夜节律的障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的R、Ar、R1、R1'、R2和n如规范中所定义，并且包括它们的药物活性盐、外消旋混合物、对映异构体和互变异构体。本发明还涉及化合物I的新型化合物、含有它们的组合物以及它们的制备方法。
• New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
  申请人：BIOPROJET

  公开号：US20130324506A1

  公开（公告）日：2013-12-05

  The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

  本专利申请涉及H4受体的新配体，它们的制备过程以及它们的治疗用途。
• EP1981880A2
  申请人：——

  公开号：EP1981880A2

  公开（公告）日：2008-10-22
• US8158668B2
  申请人：——

  公开号：US8158668B2

  公开（公告）日：2012-04-17
• [EN] USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS<br/>[FR] UTILISATION DE DERIVES DE 4-IMIDAZOLE CONTRE LES TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2007085556A2

  公开（公告）日：2007-08-02

  [EN] The present invention relates to the use of compounds of formula (I) wherein R is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, phenyl, S-phenyl or O-phenyl, which are optionally substituted by lower alkoxy or halogen, or is benzyloxy, C(O)O-lower alkyl, cycloalkyl, or is lower alkyl or lower alkoxy substituted by halogen; Ar is aryl or heteroaryl, selected from the group consisting of phenyl, naphthyl, pyridinyl, benzofuranyl, dihydrobenzofuranyl or pyrazole; R¹/R^1' are independently from each other hydrogen, hydroxy, lower alkyl, lower alkoxy or are phenyl or benzyl, which are optionally substituted by halogen; R² is hydrogen or lower alkyl; n is 1, 2, 3 or 4; and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms for the preparation of medicaments for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
  [FR] La présente invention concerne l'utilisation de composés de formule (I), dans laquelle R est hydrogène, halogène, alkyle inférieur, alcoxy inférieur, hydroxy, phényle, S-phényle ou O-phényle, éventuellement substitués par alcoxy inférieur ou halogène, ou est benzyloxy, C(O)O-alkyle inférieur, cycloalkyle, ou est alkyle inférieur ou alcoxy inférieur substitué par halogène; Ar est aryle ou hétéroaryle, sélectionné dans le groupe constitué par phényle, naphtyle, pyridinyle, benzofuranyle, dihydrobenzofuranyle ou pyrazole; R¹/R^1' sont indépendamment l'un de l'autre, hydrogène, hydroxy, alkyle inférieur, alcoxy inférieur, ou sont phényle ou benzyle, éventuellement substitués par halogène; R² est hydrogène ou alkyle inférieur; n est 1, 2, 3 ou 4; et leurs sels pharmaceutiquement actifs, mélanges racémiques, énantiomères, isomères actifs et formes tautomères, destinés à la préparation de médicaments servant au traitement de la dépression, des troubles anxieux, du trouble bipolaire, du trouble d'hyperactivité avec déficit de l'attention, des troubles liés au stress, des troubles psychotiques tels que la schizophrénie, des maladies neurologiques telles que la maladie de Parkinson, des troubles neurodégénératifs tels que la maladie d'Alzheimer, de l'épilepsie, de la migraine, de l'hypertension, de l'abus de substances psychoactives, et de troubles métaboliques tels que les troubles de la nutrition, le diabète, les complications diabétiques, l'obésité, la dyslipidémie, les troubles de la consommation et de l'assimilation d'énergie, les troubles et dysfonctionnements de l'homéostasie de la température corporelle, les troubles du sommeil et du rythme circadien, et les troubles cardiovasculaires.